SRPT – sarepta therapeutics, inc. (US:NASDAQ)
Stock Stats
News
1/16
11:51 am
srpt
Neutral
Sarepta Preliminary Results: Not What The Market Wanted To Hear [Seeking Alpha]
1/16
09:32 am
srpt
Low
Sarepta Therapeutics: Is Elevidys A Bust? [Seeking Alpha]
1/15
05:20 pm
srpt
Low
Sarepta Therapeutics (NASDAQ:SRPT) had its price target raised by analysts at Royal Bank Of Canada from $16.00 to $18.00. They now have a "sector perform" rating on the stock.
1/14
08:04 am
srpt
Medium
Sarepta Therapeutics (NASDAQ:SRPT) had its "sell" rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
1/12
12:05 pm
srpt
Low
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues [Yahoo! Finance]
11/3/2025
04:05 pm
srpt
-34.1%
BEAT
8/6/2025
04:05 pm
srpt
7.0%
BEAT
5/6/2025
04:05 pm
srpt
-23.5%
MISS
2/26/2025
04:05 pm
srpt
-3.6%
BEAT
1/14
08:04 am
Reiterates
Sell
Sell
HC Wainwright
Medium
6.1%
12/9
08:19 am
Initiates
Outperform
Wedbush
Low
-0.2%
12/9
08:19 am
Initiates
Outperform
Wedbush
Low
-0.2%
12/9
08:13 am
Initiates
Outperform
Wedbush
Low
-0.4%
12/9
08:13 am
Initiates
Outperform
Wedbush
Low
-0.4%
1/12
12:05 pm
srpt
Low
Form 8-K Sarepta Therapeutics, For: Jan 12
12/19
04:41 pm
srpt
Low
Form 4 Sarepta Therapeutics, For: Dec 18 Filed by: Chambers Michael Andrew
12/19
04:35 pm
srpt
Low
Form 8-K Sarepta Therapeutics, For: Dec 18
12/18
08:05 pm
srpt
Medium
Form 4 Sarepta Therapeutics, For: Dec 16 Filed by: Estepan Ian Michael
12/16
05:05 pm
srpt
Medium
Form 144 Sarepta Therapeutics, Filed by: Estepan Ian Michael
Show more
Top News Gainers
3/13 Sarepta Therapeutics Inc (NASDAQ: SRPT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 11.5%
2/28 Sarepta Therapeutics Inc (NASDAQ: SRPT) had its price target lowered by analysts at JPMorgan Chase & Co. from $172.00 to $160.00. They now have an "overweight" rating on the stock. 8.1%
12/23 Roche enters $1.15 bln licensing deal for Sarepta gene therapy [Reuters] 7.6%
8/8 Patient in Sarepta gene therapy trial develops serious illness; shares plunge [Reuters] 7.0%
10/31 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 6.7%
12/12 Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53 6.5%
9/10 Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram Presents at Morgan Stanley 17th Annual Global Healthcare Conference (Transcript) [Seeking Alpha] 6.3%
10/4 Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy 6.0%
11/7 Sarepta Therapeutics Announces Third Quarter 2019 Financial Results and Recent Corporate Developments 4.9%
6/4 Sarepta Therapeutics to Present at the Goldman Sachs 40th Annual Global Healthcare Conference 4.9%
Top News Decliners
8/19 Sarepta Therapeutics Receives Complete Response Letter from the US Food and Drug Administration for Golodirsen New Drug Application -15.0%
3/6 Form 4 Sarepta Therapeutics, For: Mar 04 Filed by: Wigzell Hans Lennart Rudolf -8.6%
10/4 Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram Presents Limb-Girdle Muscular Dystrophy Type 2E Functional Results (Transcript) [Seeking Alpha] -8.3%
5/12 Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -8.0%
2/26 Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments -8.0%
8/21 Pfizer Digs Deeper Into Gene Therapy, Rivaling These Biotech Stocks [Investor's Business Daily] -6.6%
1/22 Sarepta shares fall 4% after FDA documents show safety concern about drug [Reuters] -6.4%
8/7 Sarepta Therapeutics Announces Second Quarter 2019 Financial Results and Recent Corporate Developments -5.7%
8/30 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -5.4%
8/8 This Biotech Crashed On 'Erroneous' Report — Plus 2 Stocks That Diverged [Investor's Business Daily] -5.4%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3